Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | TDO2 | P48775 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001426 | 0.85 | HRH1 (0.53) | HRH1IDO1TDO2TAAR1GAA | |
| SCHEMBL4672694 | 0.82 | IDO1 (0.44) | HRH1IDO1TDO2TAAR1GAA | |
| SCHEMBL7297048 | 0.80 | SLC6A2 (0.42) | HRH1IDO1TDO2HTR2AOPRK1 | |
| SCHEMBL6001218 | 0.80 | HRH1 (0.48) | HRH1IDO1TDO2TAAR1GAA | |
| SCHEMBL14607651 | 0.79 | IDO1 (0.44) | HRH1IDO1TDO2GAAHTR2A | |
| SCHEMBL3910983 | 0.78 | TAAR1 (0.60) | HRH1IDO1TDO2TAAR1GAA | |
| SCHEMBL16371920 | 0.78 | CES2 (0.43) | HRH1IDO1TDO2TAAR1GAA | |
| SCHEMBL11994152 | 0.77 | CYP19A1 (0.43) | HRH1IDO1TDO2HTR2ACYP19A1 | |
| SCHEMBL7299070 | 0.77 | CYP19A1 (0.43) | HRH1IDO1TDO2GAAHTR2A | |
| SCHEMBL6000442 | 0.76 | HRH1 (0.52) | HRH1TAAR1HTR2ACYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1749522-A2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6051610-A | COMPOUNDS USEFUL AS NEUROPROTECTANTS, ANTICONVULSANTS, ANXIOLYTICS, ANALGESICS, MUSCLE RELAXANTS OR ADJUVANTS TO GENERAL ANESTHETICS | NPS PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | HRH1 403/4885IDO1 3661/4885TDO2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.